The week did not reopen the IPO market in any broad sense. It showed that buyers will still fund size, recognizable sponsors, and straightforward use-of-proceeds stories, but they are not extending that benefit far down the calendar. Bending Spoons priced 57,971,015 shares at $29 and filed its final prospectus on July 1; ITG priced 19,512,196 shares at $16 and then closed with the full 2,926,829-share greenshoe exercised; Lime priced 6,956,522 shares at $25; and Sinda used the week to settle into NYSE trading and point investors back to its exploration plan. Below that tier, the story was still mostly amendments, first public filings, and alternative routes to market.
Bending Spoons set the tone
Bending Spoons was the week’s only unmistakable demand story. The company’s launch range was $26 to $28, and the deal priced above that range at $29 with a syndicate led by Goldman Sachs International, J.P. Morgan, and Allen & Company. The more important detail was structural: the offering mixed 34,398,640 primary shares with 23,572,375 secondary shares, so investors were not just absorbing an exit. They were also underwriting fresh acquisition currency for a company that has built its identity around buying and remaking software and internet assets. IPOGrid reads that as the cleanest signal of the week because it combined scale, above-range pricing, and a real capital-raising purpose instead of a cosmetic listing event.
The final 424B4 also matters because it formalized one of the few offerings in this window that looked built for public investors rather than merely permitted by the market. In a week crowded with smaller foreign issuers still amending paperwork, Bending Spoons gave readers a genuine benchmark for what buyers were willing to reward: scale, sponsorship, and a business model that public investors can at least map, even if they debate the valuation.
Capital was available, but not on easy terms
ITG was the clearest reminder that execution still has a price. The company launched at $19 to $22, but priced at $16. The same pricing release said expected net proceeds were about $279.2 million and would go to repay the revolving credit facility and term loan facility; the final prospectus turned that into the week’s most explicit debt-refinancing IPO. Our take is that investors funded the company, but only after demanding a materially lower price for a leverage-cleanup story. The later full greenshoe exercise and roughly $323.4 million of net proceeds improved the finish, but it did not erase the message embedded in the discount.
Lime landed in a healthier middle ground. The company’s pricing release showed a mostly primary deal, with 6,679,791 shares sold by Lime and just 276,731 by existing holders, and said trading would begin on July 1 under LIME. The company’s 424B4 frames the proceeds as general corporate capital, not a balance-sheet rescue on the ITG model. We would frame Lime as a better-quality handoff than ITG, but still a selective one: public investors backed a known consumer platform with scale, not a speculative reopening of every growth story in the queue.
Sinda belonged to the same financed cohort even though its trading start predated the review window by a few days. The company’s pricing announcement put the deal at $12 for 17,750,000 shares, and its first-day NYSE notice said net proceeds were intended to fund a multi-year exploration and infill drilling program plus a nine-kilometer underground decline at Caracol. The June 29 final prospectus kept the name relevant to this week’s review. That is not the same caliber of signal as Bending Spoons, but it still counts as real risk capital raised for a defined operating plan.
The lower end was still messy
The rest of the calendar looked much less settled. SeeQC finally filed its public S-1 and said it intends to list on Nasdaq with Cantor and BTIG leading, but the company did not yet disclose a share count or price range in the filing. That makes it an interesting addition to the pipeline, not an execution read. The structure appears to us like a name that still has to earn price discovery.
Ticketplus was further along on paper but not yet over the line. Its July 2 F-1/A revised the proposed deal to 1,786,000 shares at $13 to $15, made clear that the closing is contingent on NYSE American listing approval, and said chairman Yethro Dinamarca Santelices would still control about 64.8% of the voting rights after the offering. Nuclea Energy was even less mature as a market event: it simply filed another F-1/A on July 1. Neither filing looked like proof that the market had broadened.
The supporting names were also a reminder to separate fresh public-paper flow from actual financings. Scribe Therapeutics finally surfaced publicly with an S-1 and a bank group that included Leerink, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities, which is more interesting than another micro-cap amendment. But it is still only a filing. And IQM Quantum Computers began trading on Nasdaq on July 2 after closing its business combination with Real Asset Acquisition Corp.; Nasdaq’s corporate action notice makes clear this was a de-SPAC conversion, not a conventional IPO. That distinction matters because the week’s headline count of new public names looked healthier than the underlying IPO tape really was.
The clean conclusion is that July opened with a functioning top tier and a still-fragile lower tier. Bending Spoons, Lime, ITG, and Sinda showed that capital is available for issuers with scale, clear sponsors, and credible use cases for proceeds. Everything below that felt more conditional. For IPO readers, that is the real update from June 29 through July 5: the market was open, but only selectively, and the gap between financable names and merely fileable names remained wide.